Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist

Neuropharmacology

Volumn 43, Issue 8, 2002, Pages 1210-1217

  Popik, P ^a   Wrobel M ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

2 methyl 6 (phenylethynyl) pyridine; Conditioned place preference; Conditioned reward; Learning; Locomotor activity; Memory; mGluR5; Morphine; MPEP; Opiates

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; MORPHINE; RECEPTOR SUBUNIT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVERSION; CONDITIONED REFLEX; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; INFORMATION RETRIEVAL; LEARNING; LEARNING TEST; LOCOMOTION; MALE; MAZE TEST; MEMORY; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; TASK PERFORMANCE;

EID: 0036951025     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00309-X     Document Type: Article

References (43)

1. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology. 153:2000;31-43.
2. Bardo M.T., Neisewander J.L. Single-trial conditioned place preference using intravenous morphine. Pharmacology Biochemistry and Behavior. 25:1986;1101-1105.
3. Barr G.A., Paredes W., Bridger W.H. Place conditioning with morphine and phencyclidine: dose dependent effects. Life Sciences. 36:1985;363-368.
4. Bespalov A., Dumpis M., Piotrovsky L., Zvartau E. Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. European Journal of Pharmacology. 264:1994;233-239.
5. Bisaga A., Popik P. In search of a new pharmacological treatment of drug addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug and Alcohol Dependence. 59:2000;1-15.
6. Bordi F., Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Progress in Neurobiology. 59:1999;55-79.
7. Carr G.F., Fibiger H.C., Phillips A.G. Condition place preference as a measure of drug reward. Liebman J., Cooper S.J. The neuropharmacological basis of reward. 1989;264-319 Clarendon Press, Oxford, UK.
8. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., Conquet F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci. 4:2001;873-874.
9. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology. 37:1997;205-237.
10. Fundytus M.E., Coderre T.J. Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence. British Journal of Pharmacology. 113:1994;1215-1220.
11. Fundytus M.E., Ritchie J., Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype- selective metabotropic glutamate receptor antagonists. British Journal of Pharmacology. 120:1997;1015-1020.
12. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 38:1999;1493-1503.
13. Haertzen C.A., Kocher T.R., Miyasato K. Reinforcements from the first drug experience can predict later drug habits and/or addiction: results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug and Alcohol Dependence. 11:1983;147-165.
14. Heinrichs S., Menzaghi F., Schulteis G., Koob G.F., Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behavioural Pharmacology. 6:1995;74-80.
15. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology. 36:1997;1511-1516.
16. Hlinak Z., Krejci I. Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice. Behavioural Brain Research. 117:2000;147-151.
17. Itoh J., Nabeshima T., Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology. 101:1990;27-33.
18. Itoh J., Nabeshima T., Kameyama T. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. European Journal of Pharmacology. 194:1991;71-76.
19. Klodzinska A., Chojnacka Wojcik E., Palucha A., Branski P., Popik P., Pilc A. Potential anti-anxiety and anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology. 38:1999;1831-1839.
20. Kuzmin A., Patkina N., Pchelintsev M., Zvartau E. Isradipine is able to separate morphine-induced analgesia and place conditioning. Brain Research. 593:1992;221-225.
21. Lister R.G. The use of a plus maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
22. Lovinger D.M., McCool B.A. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGluR2 or 3. Journal of Neurophysiology. 73:1995;1076-1083.
23. Manzanedo C., Aguilar M.A., Rodriguez-Arias M., Minarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. Behavioural Brain Research. 121:2001;189-197.
24. Movsesyan V.A., Oleary D.M., Fan L., Bao W.L., Mullins P.G.M., Knoblach S.M., Faden A.I. mGluR5 antagonists 2-methyl-6-(Phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N- methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics. 296:2001;41-47.
25. Mucha R.F., Iversen S.D. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology. 82:1984;241-247.
26. Mucha R.F., Van der Kooy D., O'Shaughnessy M., Bucenieks P. Drug reinforcement studied by the use of place conditioning in the rat. Brain Research. 243:1982;91-105.
27. Narita M., Aoki T., Ozaki S., Yajima Y., Suzuki T. Involvement of protein kinase C gamma isoform in morphine- induced reinforcing effects. Neuroscience. 103:2001;309-314.
28. Parsons C.G., Danysz W., Quack G. Glutamate in CNS disorders as a target for drug development: An update. Drug News and Perspectives. 11:1998;523-569.
29. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by NMDA receptor antagonist, memantine. Journal of Pharmacology and Experimental Therapeutics. 280:1997;854-865.
30. Popik P., Kolasiewicz W. Mesolimbic NMDA receptors are implicated in the expression of conditioned morphine reward. Naunyn-Schmiedebergs Archives of Pharmacology. 359:1999;288-294.
31. Popik P., Kozela E., Pilc A. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. British Journal of Pharmacology. 130:2000;1425-1431.
32. Rao A.M., Hatcher J.F., Dempsey R.J. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neuroscience Letters. 293:2000;1-4.
33. Schulz B., Fendt M., Gasparini F., Lingenhohl K., Kuhn R., Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology. 41:2001;1-7.
34. Shippenberg T.S., Emmett Oglesby M.W., Ayesta F.J., Herz A. Tolerance and selective cross-tolerance to the motivational effects of opioids. Psychopharmacology. 96:1988;110-115.
35. Spooren W.P., Gasparini F., Salt T.E., Kuhn R. Novel allosteric antagonists shed light on mGlu(5) receptors and CNS disorders. Trends in Pharmacological Sciences. 22:2001;331-337.
36. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. Journal of Pharmacology and Experimental Therapeutics. 295:2000;1267-1275.
37. Stinus L., Le Moal M., Koob G.F. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience. 37:1990;767-773.
38. Tallaksen-Greene S.J., Kaatz K.W., Romano C., Albin R.L. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Research. 780:1998;210-217.
39. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology. 132:2001;1423-1430.
40. Tzschentke T.M., Schmidt W.J. N-methyl-D-aspartic acid-receptor antagonists block morphine- induced conditioned place preference in rats. Neuroscience Letters. 193:1995;37-40.
41. Vandergriff J., Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine- withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology. 38:1999;217-222.
42. White F.J., Kalivas P.W. Neuroadaptations involved in amphetamine and cocaine addiction. Drug and Alcohol Dependence. 51:1998;141-153.
43. White N.M., Carr G.D. The conditioned place preference is affected by two independent reinforcement processes. Pharmacology Biochemistry and Behavior. 23:1985;37-42.